These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33031051)

  • 1. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
    Harada D; Kashiwagi H; Ueyama K; Oriyama K; Hanioka Y; Sakamoto N; Kondo K; Kishimoto K; Izui M; Nagamatsu Y; Yamada H; Tanaka H; Namba N; Seino Y
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1391-1397. PubMed ID: 33031051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
    J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
    Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
    J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
    Zeitlin L; Rauch F; Plotkin H; Glorieux FH
    Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
    Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of alendronate on quality of life in children with osteogenesis imperfecta.
    Seikaly MG; Kopanati S; Salhab N; Waber P; Patterson D; Browne R; Herring JA
    J Pediatr Orthop; 2005; 25(6):786-91. PubMed ID: 16294137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
    Dimeglio LA; Ford L; McClintock C; Peacock M
    J Pediatr Endocrinol Metab; 2005 Jan; 18(1):43-53. PubMed ID: 15679068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.